BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

We are proud to be recognized on the Deloitte 2020 Technology Fast 500 list
Patients First

Patients First

Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone. This is especially true for the more than 20 million individuals living with chronic, severe pain in the United States.

At BDSI, our mission extends beyond providing access to therapeutic solutions. We believe advocating for patients—being a voice for awareness and change—is an integral part of helping individuals make progress in their lives. This is who we are.

Image of woman

"If you could see my pain, you would see the beautiful mask of my face, and under it, you would see every natural disaster happening at the same time."

"You can't judge a person just by looking at them. On the outside, they may look very normal and healthy, but on the inside, they may be experiencing a constant firestorm of pain."

Image of man

Recent BDSI News

May 6, 2021

Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery

Read more
April 20, 2021

RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021

Read more
March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
May 10, 2021BDSI $3.18/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.